REFRACTORY EPITHELIOID SARCOMA

Clinical trials for REFRACTORY EPITHELIOID SARCOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY EPITHELIOID SARCOMA trials appear

Sign up with your email to follow new studies for REFRACTORY EPITHELIOID SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New immune attack on rare, aggressive cancers

Disease control Ongoing

This study is testing a combination of two immunotherapy drugs, tiragolumab and atezolizumab, for children and adults with rare, aggressive cancers that have come back or stopped responding to standard treatments. These cancers are missing specific genes (SMARCB1 or SMARCA4). The…

Matched conditions: REFRACTORY EPITHELIOID SARCOMA

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 23, 2026 15:15 UTC

REFRACTORY EPITHELIOID SARCOMA

Get alerted when new REFRACTORY EPITHELIOID SARCOMA trials appear

New immune attack on rare, aggressive cancers